The goal of the research program is to develop immune tolerance to combined HLA haplotype matched living related kidney and hematopoietic cell transplants in order to remove the requirement for the lifelong use of maintenance immunosuppressive drugs and to improve long term graft survival. The program builds on the success of inducing tolerance in patients with combined HLA matched living related kidney and hematopoietic cell transplants during the previous grant period using a posttransplant conditioning regimen of total lymphoid irradiation (TLI) and rabbit anti-thymocyte globulin (ATG). The regimen was shown to be safe and effective in achieving persistent mixed chimerism without graft versus host disease (GVHD). This allowed for immunosuppressive drug withdrawal without kidney allograft rejection episodes in chimeric patients. In addition, patients given HLA haplotype matched hematopoietic cell transplants for the treatment of leukemia and lymphoma using the TLI/ATG conditioning regimen developed persistent engraftment without acute GVHD. The results of these clinical studies performed during the previous grant period provide the basis for the proposed new trial for 25 HLA haplotype matched patients. Patients that achieve stable chimerism without GVHD or evidence of rejection will be withdrawn from immunosuppressive drugs at 6 months posttransplant. Patients will be monitored for evidence of the establishment of immune tolerance by testing specific immune unresponsiveness to donor alloantigens in vitro and by performing serial gene microarray testing of peripheral blood mononuclear cells to look for the posttransplant acquisition of a previously described """"""""tolerant"""""""" gene expression pattern. Patients will also be monitored for immune reconstitution by studying the recovery of T cell subsets;T cell excision circles (TRECs), in vitro immune responses to new and recall microbial antigens, incidence of infections, and responses to vaccination. Outcome parameters will be compared at that of an equal number of HLA haplotype matched transplant patients given conventional therapy. The research project will interact with all other Projects and with Cores.

Public Health Relevance

The results of the proposed studies are expected to allow for the discontinuation of immunosuppressive drugs in kidney transplant patients, and avoid cumulative drug side effects and long term graft loss.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL075462-09
Application #
8470682
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
9
Fiscal Year
2013
Total Cost
$337,036
Indirect Cost
$112,072
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Kawai, Tatsuo; Leventhal, Joseph; Wood, Kathryn et al. (2018) Summary of the Third International Workshop on Clinical Tolerance. Am J Transplant :
Scandling, John D; Busque, Stephan; Lowsky, Robert et al. (2018) Macrochimerism and clinical transplant tolerance. Hum Immunol 79:266-271
Hongo, David; Tang, Xiaobin; Zhang, Xiangyue et al. (2017) Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129:1718-1728
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Simonetta, Federico; Alvarez, Maite; Negrin, Robert S (2017) Natural Killer Cells in Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation. Front Immunol 8:465
Zhang, Hong; Gregorio, Josh D; Iwahori, Toru et al. (2017) A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes. Proc Natl Acad Sci U S A 114:1988-1993
Chen, Yi-Bin; Efebera, Yvonne A; Johnston, Laura et al. (2017) Increased Foxp3+Helios+Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant 23:625-634
Pierini, Antonio; Nishikii, Hidekazu; Baker, Jeanette et al. (2017) Foxp3+ regulatory T cells maintain the bone marrow microenvironment for B cell lymphopoiesis. Nat Commun 8:15068
Mavers, Melissa; Maas-Bauer, Kristina; Negrin, Robert S (2017) Invariant Natural Killer T Cells As Suppressors of Graft-versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 8:900
Revelo, Xavier S; Ghazarian, Magar; Chng, Melissa Hui Yen et al. (2016) Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance. Cell Rep 16:717-30

Showing the most recent 10 out of 70 publications